Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 6/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21551364 | 1.00 | SQOR (0.40) | SQORCNR1PLAUGRM5NUDT1 | |
| SCHEMBL30931890 | 0.91 | GRM5 (0.40) | SQORCNR1PLAUGRM5NUDT1 | |
| SCHEMBL21551396 | 0.91 | GRM5 (0.40) | SQORCNR1PLAUGRM5NUDT1 | |
| SCHEMBL23375774 | 0.86 | NUDT1 (0.40) | SQORCNR1PLAUGRM5NUDT1 | |
| SCHEMBL29928851 | 0.81 | BCL2L1 (0.38) | GRM5NUDT1MCL1BCL2L1LTB4R | |
| SCHEMBL21551160 | 0.81 | BCL2L1 (0.38) | GRM5NUDT1MCL1BCL2L1LTB4R | |
| SCHEMBL28542186 | 0.80 | MCL1 (0.38) | SQORCNR1GRM5NUDT1MCL1 | |
| SCHEMBL21551106 | 0.78 | LMNA (0.52) | CNR1MCL1MRGPRX4BCL2L1LTB4R | |
| SCHEMBL30931797 | 0.78 | LMNA (0.52) | CNR1MCL1MRGPRX4BCL2L1LTB4R | |
| SCHEMBL28547582 | 0.78 | MCL1 (0.40) | NUDT1MCL1BACE1MRGPRX4BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-20230011571-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | BP ASSET V, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-4058021-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | BP Asset V, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011571-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | FURIN, LGMN, PLAU | SQOR 1378/4885CNR1 4664/4885PLAU 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.